Now I have all the information I need. Let me write the final consolidated review.

## Summary

The paper proposes an end-to-end multi-view diabetic retinopathy (DR) grading framework that eliminates dependency on costly external annotations. A Grade-Activated Lesion Proposal (GALP) module derives grade-conditioned evidence maps from stage-wise auxiliary classifiers and selects Top-K high-activation regions as "lesion proposals," while a Cross-View Lesion Expert-Guided Regional Fusion (LGRF) module uses expert routing with contextual gating to selectively fuse proposal features across views. On two benchmarks, the lesion-free variant matches or surpasses several externally-informed methods, and with lesion annotations achieves new SOTA on MFIDDR.

## Strengths

- **Strong empirical results without external annotations**: The lesion-free variant achieves 83.9% Acc on MFIDDR, surpassing all end-to-end baselines (best prior: ETMC 81.5%) and matching or exceeding several externally-informed methods (LFMVDR-with-lesion 82.2%, CVSA-with-vessel 82.6%). On DRTiD, it achieves 76.0% Acc, outperforming CrossFiT (75.6%) which requires OD and macula coordinates. This is a meaningful practical result demonstrating that annotation dependency can be substantially reduced.

- **Consistent improvement on clinically difficult grades**: Table 2 shows Grade 3 F1 improves from 68.1% (MVCINN) to 74.1% without lesion annotations, and Grade 2 F1=62.5% surpasses LFMVDR-with-lesion (59.0%). Moderate DR is a key referral decision point, making this clinically meaningful.

- **Complementary to external annotations**: The method improves further to 84.6% Acc when lesion information is incorporated via SPADE (Table 1), establishing SOTA. Grade 4 F1 rises from 36.0% to 51.6%, showing the framework can leverage external cues when available rather than merely substituting for them.

- **Coherent end-to-end pipeline with inference-time independence**: Unlike methods requiring a separate segmentation model at inference (SMVDR, LFMVDR), GALP generates proposals on-the-fly from the grading model itself, eliminating brittleness from upstream segmentation errors. The entire system is trained with a single objective (Eq. 20).

- **Evaluated across two distinct multi-view configurations**: Results on both a four-view (MFIDDR, 224×224, ImageNet pretrained) and two-view (DRTiD, 512×512, EyePACS pretrained) dataset suggest generalizability beyond a single experimental setup.

## Weaknesses

### Fatal
None.

### Major

- **The core "lesion proposal" narrative is structurally unsupported — no direct evidence that selected regions correspond to lesions**: The paper's central claim is that GALP produces "lesion proposals" that "act as surrogates for costly expert cues" (Abstract, Section 3.2, Conclusion). This rests on the assumption that high-activation CAM regions correspond to lesions. However, CAMs are well-known to highlight any grade-discriminative region — vessels, optic disc, artifacts, or large background areas — not specifically lesions. The paper states these regions are "interpreted as grade-related (i.e., lesion) areas" (Section 3.2), but provides zero quantitative validation. The MFIDDR dataset provides lesion segmentation masks (Section 4.1: "The provider also releases lesion segmentation masks"), making validation straightforward (e.g., computing IoU between proposal regions and ground-truth lesion masks). Without this validation, the mechanism could be providing region-based attention that helps for reasons unrelated to lesion localization, and the paper's explanatory narrative may not match its actual mechanism.

- **The ablation study does not isolate whether CAM-based proposal selection specifically matters versus auxiliary supervision**: Table 4 shows that removing GALP entirely drops accuracy from 83.9% to 82.7% (−1.2%). But GALP bundles two distinct contributions: (a) the auxiliary classification loss that strengthens intermediate feature discriminability (Eq. 2), and (b) the Top-K CAM-based region selection that produces "lesion proposals" (Eq. 5–7). The ablation removes both simultaneously. There is no control that keeps the auxiliary loss but replaces CAM-based selection with random region selection or uniform token downsampling. Similarly, "w/o Experts" (82.6%) removes the MoE routing but does not compare against standard multi-head cross-attention on the same proposal tokens — leaving it unclear whether the expert routing mechanism specifically helps versus simply adding capacity. These confounds mean the ablation cannot confirm that the claimed "lesion proposal" mechanism drives the observed gains.

### Minor

- **The α=50% optimal retention rate raises questions about proposal selectivity**: The hyperparameter study (Fig. 3) shows the best accuracy at α=50%, meaning half of all spatial tokens are retained as "lesion proposals." At this retention rate, the mechanism is not highly selective — it functions more as a moderate downsampling than a lesion-specific filter. This indirectly undermines the "lesion proposal" framing, since if the method were truly identifying lesion-specific regions, one might expect a much lower retention rate to be optimal. The paper does not analyze what fraction of ground-truth lesion area is covered by selected regions at different α values, which could clarify whether the mechanism is doing meaningful lesion filtering or just a beneficial attention/downsampling operation.

- **No qualitative validation of proposal quality**: The paper lacks any visualization of GALP evidence maps or selected Top-K regions overlaid on fundus images with ground-truth lesion masks. For a paper whose core contribution is about generating "lesion proposals," this is a conspicuous gap. Even a few qualitative examples would help readers assess whether the selected regions plausibly correspond to lesions.

- **The bootstrapping problem is unaddressed**: GALP proposals depend on the model's current grade predictions (ŷ), which are poor early in training. The paper does not discuss or analyze how proposal quality evolves during training or whether any warm-up strategy is needed to mitigate early poor proposals.

### Trivial
None.

## Nice-to-Haves

- Report backbone architectures for all compared methods in the comparison tables, so readers can assess whether improvements come from the proposed modules versus backbone strength differences.
- A cyclic adjacency analysis: with N=4 views and j=i+1 fusion, each view only fuses with one other view per stage. An ablation comparing cyclic vs. fully-connected cross-view fusion would clarify whether this design choice matters.
- Multiple-run statistics (standard deviations) for the main results, particularly given the relatively small margins over some baselines.

## Removed Points

These points are flagged to be removed, treat them with caution.

- **Unfair baseline comparison due to unreported backbones** (Harsh Critic #3): The paper compares against published numbers from prior work, which is standard practice in this field. The paper explicitly matches backbone pretraining where possible (ImageNet for MFIDDR consistent with CVSA, EyePACS for DRTiD consistent with CrossFiT). Reporting all backbones would be informative but is a nice-to-have, not a major weakness. Removed to Nice-to-Haves.

- **No standard deviations / multiple-run statistics** (Harsh Critic): Single-run evaluation is the norm for large-scale benchmarks in this domain. This is a nice-to-have, not a weakness that affects the validity of the results.

- **Different preprocessing/image sizes across datasets** (Harsh Critic): The paper follows each dataset's established protocols for fair comparison with prior work. This is a design choice for compatibility, not a confound.

- **Abstract overclaims "surrogates"** (Harsh Critic): The 0.7% gap between w/o lesion (83.9%) and with lesion (84.6%) actually supports the claim that proposals are effective surrogates — the remaining gap is small. The claim "substantially reduce annotation needs" is well-supported. However, the claim that proposals "act as surrogates for external cues" is weakened by the lack of validation that proposals actually localize lesions, which is already captured in Major weakness #1.

- **Missing related works** (implied by Harsh Critic): Per hard rules, I do not flag missing related works.

## Novel Insights

The paper reveals an interesting tension in its own results: the α=50% optimal retention rate suggests the "lesion proposal" mechanism may function more as a soft spatial attention/downsampling operation rather than a precise lesion localizer. If the proposals were truly lesion-specific, one would expect much more aggressive filtering to be beneficial. This observation, combined with the lack of lesion-localization validation and the confounded ablation, suggests the method may work well for reasons that are partially orthogonal to its stated mechanism — the auxiliary supervision signal and the moderate token downsampling may be the real drivers, not lesion-localized region selection.

## Suggestions

- **Compute IoU/overlap between Top-K proposal regions and ground-truth lesion masks** on MFIDDR. This is the single most important experiment to add. If IoU is high, it validates the core narrative; if it is low, the paper should reframe its contribution around region-based attention rather than "lesion proposals."

- **Add an ablation with auxiliary loss + random region selection** (same K regions, no CAM scoring). If this matches GALP's performance, the "lesion proposal" narrative needs substantial reframing; if it underperforms, it provides strong evidence that CAM-based selection specifically helps.

- **Add qualitative visualizations** of evidence maps and selected regions overlaid on fundus images with lesion ground truth, at minimum for a few representative cases.

## Score and Decision

**Calibration anchors:**

| Paper | Path | Avg Score | Comparison |
|-------|------|-----------|------------|
| Sapiens2 | /home/wg25r/review_agent/human_reviews_2026/IVAlYCqdvW.md | 7.0 | Strong engineering, thorough evaluation, clear validated contributions. Our paper has weaker evidence for its mechanistic claims. |
| Screener | /home/wg25r/review_agent/human_reviews_2026/i7YnUW0uWg.md | 6.0 | Self-supervised method with some missing baselines but accepted. Our paper has similar issues but also lacks validation of core mechanistic claim. |
| ProConMV | /home/wg25r/review_agent/human_reviews_2026/9gc58FeBba.md | 5.0 | Multi-view DR framework with unsupported interpretability claims. Similar domain, similar overclaim pattern. |
| PPBoost | /home/wg25r/review_agent/human_reviews_2026/0EXuliYnfW.md | 4.0 | Pseudo-label-based surrogate for annotations, weaker validation. Our paper has stronger empirical results. |
| MI-Grad-CAM | /home/wg25r/review_agent/human_reviews_2026/C5Dgtmk7ho.md | 3.0 | CAM overclaims without proper validation. Our paper has the same CAM-overclaim pattern but much stronger downstream task results. |
| LTH | /home/wg25r/review_agent/human_reviews_2026/cESVZ0SfjA.md | 1.5 | Claims lesion segmentation as "implicit labels" without validation, no formal theory. Our paper is much stronger than this. |

Our paper sits above the low-scoring CAM-overclaim anchors (1.5–3.0) because it has genuinely strong empirical results on two benchmarks and a real practical contribution. It sits below the medium-high anchors (6.0–7.0) because those papers either validated their claims more thoroughly or had smaller gaps between narrative and evidence. It is comparable to ProConMV (5.0) which had similar overclaim issues in the same domain, but our paper has stronger empirical results. PPBoost (4.0) is a reasonable lower bound. I place this paper at **5.5**: the empirical contribution is real and meaningful, but the two Major weaknesses — unvalidated "lesion proposal" narrative and confounded ablation — prevent higher confidence in the paper's explanatory claims.

MY FINAL SCORE: <pineapple>5.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>